H1N1 vax monitoring flags potential risks

The CDC says that their monitoring programs have uncovered a very small increased risk for Guillain-Barre syndrome, Bell's palsy and thrombocytopenia among people who were injected with the H1N1 vaccine. But the increased risk is so small, the CDC says it can't tell if the apparent increase in danger is the result of a problem with the vaccine or simply the result of better monitoring. "Because the effects are so small, it is hard to say whether it is due to chance or a real effect," said Dr. Stephen Redd, director of the CDC's influenza coordination unit. Story

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.